Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Up 5.99%
As of Friday, July 31, Acumen Pharmaceuticals, Inc.’s ABOS share price has surged by 5.99%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Commentary & Analysis
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 5.92%
As of Wednesday, July 29, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Up 7.27%
As of Tuesday, July 28, Acumen Pharmaceuticals, Inc.’s ABOS share price has surged by 7.27%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 10.47%
As of Wednesday, July 15, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 10.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Acumen Pharmaceuticals, Inc.’s (ABOS) Stock Is Down 5.14%
As of Wednesday, July 15, Acumen Pharmaceuticals, Inc.’s ABOS share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $155.3 | $252.6 | 25% |
|
| Shares Out (Mil) | 63.2 | 52.3 | 53% |
|
| Institutional Ownership | 69.2% | 92.1% | 43% |
|
| Float (Mil) | 37.0 | 40.2 | 41% |
|
| Beta | 0.35 | 0.95 | 20% |
|
| Avg Daily Volume (000s) | 330 | 455 | 53% |
|
| Price Change (52-week) |
47.3% | 52.9% | 79% |
|
| Growth | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (75.4%) | (9.9%) | 3% |
|
| EPS (5yr) | 35.2% | 16.0% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (68.0%) | (15.6%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.405) | ($1.585) | ($1.507) | |
| Month Ago EPS | ($0.405) | ($1.585) | ($1.507) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.460) | ($1.836) | ($1.392) | |
| Year/Year Chg | 23.5% | (20.9%) | (28.7%) | |
| Financials | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($113) | ($43) | 10% |
|
| EPS (TTM) | ($1.850) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($106) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $22 | $5 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $17 | $5 | 32% |
|
| Enterprise Value (Q1) (Mil) | $60 | $180 | 17% |
|
| Valuation | ABOS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.78 | 2.56 | 47% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ABOS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (67.0%) | (49.8%) | 9% |
|
| ROE | (93.2%) | (55.5%) | 10% |
|
| Liabilities to Assets | 34.5% | 30.3% | 25% |
|
| F-Score | 2 | 3 | 7% |
|
Acumen Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
